ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: L01 • ACR Convergence 2024

    Targeted Exosite Inhibition of STING Activation of TBK1 Selectively Blocks Type I Interferon and NFκB Responses for Treatment of Autoimmune Diseases

    Matthew Martin1, Erik Wilker1, Diana Gikunju1, Usha Narayanan1, Unnati Pandya1, Vijetha Prakash1, Ashley Edwards1, Sameer Kawatkar1, Tenghui Chen1, Ragunath Chandran1, Sai Sunder1, Sumathi Biradar1, Joerg Distler2, Alexandra Joseph1, Stephanos Ioannidis1 and Bhavatarini Vangamudi1, 1Exo Therapeutics, Cambridge, MA, 2Exo Therapeutics, Düsseldorf, Germany

    Background/Purpose: The cGAS-TBK1-STING pathway senses nucleic acids for innate immunity. Aberrant activation of the pathway is linked to autoimmune diseases including Systemic and Cutaneous Lupus…
  • Abstract Number: L03 • ACR Convergence 2024

    CD9 Expressing T Follicular Helper Cells Are a Highly Functional Subset Expanded in Systemic Lupus Erythematosus

    Kyleigh Brimmer1, Olivia Antao1, Daniel Mayer1, Gina Sanchez1, Rebecca Francis1, Htay Htay Kyi2, Mary Salim2, Boyan Xia2, Eugenio Capitle2 and Jason Weinstein1, 1Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ, 2Division of Allergy, Immunology and Rheumatology, University Hospital, Newark, NJ

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by the generation of autoantibodies that promote tissue injury. The development of pathogenic autoantibody-secreting B cells in lupus…
  • Abstract Number: L10 • ACR Convergence 2024

    Neuroimmune Modulation in Adults with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological or Targeted Synthetic DMARDs: Results at 12 and 24 Weeks from a Randomized, Sham-Controlled, Double-Blind Pivotal Study

    John Tesser1, Joshua June2, Pendleton Wickersham3, Jane Box4, Guillermo Valenzuela5, Angela Crowley6, Nikila Kumar7, Norman Gaylis8, Gordan Lam9, David Ridley10, Gineth Paola Pinto-Patarroyo11 and David Chernoff12, 1Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 2Great Lakes Center of Rheumatology, Lansing, MI, 3Arthritis Associates PA, San Antonio, TX, 4DJL Clinical Research, PLLC, Charlotte, NC, 5Guillermo Valenzuela MD PA/ IRIS Rheumatology, Plantation, FL, 6Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, 7Arizona Arthritis & Rheumatology Associates, Scottsdale, AZ, 8Arthritis & Rheumatic Disease Specialties, Aventura, FL, 9Arthritis & Osteoporosis Consults of the Carolinas, Charlotte, NC, 10St. Paul Rheumatology, Eagan, MN, 11Annapolis Rheumatology, Fairfax, VA, 12SetPoint Medical, Sausalito, CA

    Background/Purpose: In this study, we evaluated the safety and efficacy of an implantable, cervical vagus nerve stimulation device for treatment of RA. Methods: This randomized,…
  • Abstract Number: L12 • ACR Convergence 2024

    A-319, a CD3 X CD19 T Cell Engager (TCE), for the Treatment of Severe/Refractory SLE: Early Evidence of Rapid Reset of Disease-Specific Autoimmunity

    Chunli Mei1, Xin Guan1, Bin Wu2, Mengjiao Li1, Xiaojing Liu1, Xi Chen1, You Song1, Weiwei Wang1, Cheng Wang1, Huiling Mei1, Xiaoru Duan1, Lijuan Jiang1, Wenlin Qiu1, Likai Yu1, Yuhong Liu1, Xing Zhao3, Xuanfan Zhong3, Shengjie Xue3, Wuzhong Shen3, Ying Tan3, Guojian Yu3, Guiyun Tu3, Hanyang Chen3, Amy Sun3, Xiaoqiang Yan3, Anbing Huang1, Rong Du1 and Qiubai Li1, 1Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 2Department of Rheumatology and Immunology of the First People’s Hospital of Jingzhou, Jingzhou, China, 3ITabMed Ltd. Changchun, Shanghai, China

    Background/Purpose: CD19 CAR T treatment has demonstrated clinical benefits to patients with severe/refractory systemic lupus erythematosus (SLE), possibly due to resetting autoimmunity. A-319, a highly…
  • Abstract Number: L19 • ACR Convergence 2024

    Efficacy and Safety of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Phase 3 Study and a Pooled Analysis of Two Prospective Trials

    Alexei Grom1, Uwe Ullman2, Adnan Mahmood3, Josefin Blomkvist3, Brian Jamieson4 and Fabrizio De Benedetti5, 1Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, OH, 2Sobi, Basel, Switzerland, 3Sobi, Stockholm, Sweden, 4Sobi, Inc., Morrisville, NC, 5Bambino Gesu Children's Hospital, Rome, Italy

    Background/Purpose: MAS is a life-threatening complication of Still’s disease, characterized by interferon-gamma (IFNg)-driven macrophage activation and systemic hyperinflammation. Emapalumab, an anti-IFNg antibody, binds free and…
  • Abstract Number: 0860 • ACR Convergence 2024

    Integrated Metabolic and Immunologic Analyses Reveal Distinctive Features of Comorbid Cancer in Patients with Autoimmune Diseases

    Xiangyi Shen1, Xu Jiang2, Yangzhige He2 and Huaxia Yang3, 1Tsinghua University, Beijing, China, 2National Infrastructure for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 3Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    Background/Purpose: Autoimmune diseases (AIDs) increase the risk of cancer and impose a substantial socioeconomic burden worldwide. However, the biological characteristics of cancer as a comorbidity…
  • Abstract Number: 0940 • ACR Convergence 2024

    Trans-endothelial Migration of Synovial Fibroblasts Promotes Arthritis Severity Through a PKD1-mediated Feedback Loop

    Jaeyeon Kim, Richard Ainsworth and Nunzio Bottini, Cedars-Sinai Medical Center, Los Angeles, CA

    Background/Purpose: The application of single cell genomic approaches to the study of rheumatoid synovium has recently enabled scientists to study the complex relationship between different…
  • Abstract Number: 1107 • ACR Convergence 2024

    Investigating Pyrexia of Unknown Origin: A Rheumatologist’s Perspective

    Carine Moezinia1, Jan Nouza2, Beatrice Hornstein-Lasry2, Luai Kawar2, Asim Khan2 and Jessica Manson2, 1University College London Hospital, London, England, United Kingdom, 2University College London Hospital, London, United Kingdom

    Background/Purpose: Pyrexia of Unknown Origin (PUO) is defined as a fever above 38.3°C recorded on several occasions, that evades diagnosis for at least 3 weeks.…
  • Abstract Number: 1304 • ACR Convergence 2024

    Assessing Knowledge and Aptitude in Antinuclear Antibody Testing Among Internal Medicine Residents

    Dania Kaur1, Fizza Zulfiqar2, Akanksha Sharma3, Muhammad Bilal4, Rida Fatima4 and Abhinav Vyas5, 1North Alabama Medical Center, Muscle Shoals, AL, 2Trinity Health Oakland/Wayne State University, Pontiac, MI, 3UPMC Mercy hospital, Pittsburgh, PA, Pittsburgh, PA, 4Bassett Medical Center, Cooperstown, NY, 5Vanderbilt University Medical Center, Nahville, TN

    Background/Purpose: Testing for antinuclear antibodies (ANA) is essential for diagnosing autoimmune and rheumatologic diseases. The testing has become increasingly popular in primary and specialized clinics,…
  • Abstract Number: 1533 • ACR Convergence 2024

    Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, Effectively Depletes Low-Expressing CD20+ B Cells in Preclinical Models of Autoimmune Disease

    Racquel Domingo-Gonzalez1, Isabelle Baribaud2, Shrishti Tyagi1, Kevin Hart1, Ryan Eberwine2, Angus Sinclair1, Albert Candia1, Bruce Keyt1, Merle Elloso2, Maya Kotturi1 and Mary Beth Harler1, 1IGM Biosciences, Inc., Mountain View, CA, 2IGM Biosciences, Inc., Doylestown, PA

    Background/Purpose: B cell depletion therapy (BCDT) with conventional IgG mAbs has been employed for the treatment of autoimmune (AI) disease for ~20 years; however, many…
  • Abstract Number: 1659 • ACR Convergence 2024

    Shared Lung and Joint T Cell Repertoire in Early Rheumatoid Arthritis Driven by Cigarette Smoking

    Koen Venken1, Matthias Jarlborg1, Frederik Stevenaert2, Thomas Malfait3, Carolien Vlieghe1, Yann Abraham2, Teddy Manuello1, Tine Decruy1, Stijn Van Hee1, Hans Wils2, Pieter Peeters2, Philippe Carron4, Filip Van den Bosch3, Viggo Van Tendeloo2, Bart Lambrecht1, Ruth Wittoek5, Peggy Jacques6 and Dirk Elewaut7, 1VIB Center for Inflammation Research - Ghent University, Ghent, Belgium, 2Janssen Research and Development, Beerse, Belgium, 3Ghent University Hospital, Ghent, Belgium, 4UZ Gent, Gent, Belgium, 5Dept. of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium, 6University Hospital of GHent, Gent, Belgium, 7Ghent University and VIB Center for Inflammation Research, Ghent, Belgium

    Background/Purpose: Cigarette smoking has been associated with the production of anti-citrullinated protein antibodies (ACPA) and an increased risk of developing rheumatoid arthritis (RA) in individuals…
  • Abstract Number: 1787 • ACR Convergence 2024

    Linking Transcriptomic Profiles of Kidney and Blood Samples Provides Insight into Identification of Lupus Nephritis

    Andrea Daamen1, Kathryn Kingsmore2, Prathyusha Bachali3, Nan Shen4, Amrie Grammer5 and Peter Lipsky1, 1AMPEL BioSolutions, Charlottesville, VA, 2AMPEL BioSolutions, Charlottesville, 3AMPEL BioSolutions, Redmond, WA, 4Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jaiotong University School of Medicine, Shanghai, CN, Shanghai, China (People's Republic), 5AMPEL LLC, Charlottesville, VA

    Background/Purpose: Current clinical methods to diagnose and evaluate the severity of lupus nephritis (LN) rely on identification of kidney dysfunction followed by invasive kidney biopsies.…
  • Abstract Number: 1861 • ACR Convergence 2024

    CD8T Cells Depletion Promotes Human Tph/Tfh Cells Proliferation and Sjogren Syndrome Like Symptoms Without Graft versus Host Diseases in PBMC Transferred-humanized Mice

    Yuzo Koda1, Piruzyan Mariam1, Sota Fujimori1, Ryota Sato2 and Sayuka Kato1, 1Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, 2Mitsubishi Tanabe Pharma Corporation, Brighton, MA

    Background/Purpose: Peripheral helper T (Tph) and follicular helper T (Tfh) cells are known to play a central role in the interaction between T and B…
  • Abstract Number: 1985 • ACR Convergence 2024

    Underlying Autoimmune Disease Has Not Limited Immune Checkpoint Inhibitor Use or Increased Mortality Risk During Cancer Treatment of US Veterans

    Madeline O’Sullivan1, grant Cannon2, Sauer brian3, Jorge Rojas4, Gary Kunkel5, Jessica A Walsh6, Punyasha Roul7, shardool Patel1, Joshua Baker8, Bryant England9 and Tawnie Braaten1, 1University of Utah, Salt Lake City, UT, 2University of Utah and Salt Lake City VA, Salt Lake City, UT, 3Salt Lake City VA/University of Utah, Salt Lake City, UT, 4Seattle VA, Mexico, Mexico, 5University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 6Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, 7UNMC, Omaha, NE, 8University of Pennsylvania, Philadelphia, PA, 9University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Immune checkpoint inhibitors (ICIs) can cause a variety of immune-related adverse events (irAEs) affecting multiple organ systems, and patients with pre-existing autoimmune disease (AID)…
  • Abstract Number: 2172 • ACR Convergence 2024

    A Novel Cohort to Assess Longitudinal Glucocorticoid Toxicity in Individuals with Rheumatic Diseases: Objectives, Design, and Initial Baseline Characteristics

    Naomi Patel1, Miao Lin1, Bohang Jiang1, Isha Jha1, Grace McMahon1, Aubree E. McMahon1, Yuqing Zhang2, Hyon K. Choi3, Zachary Wallace4 and John Stone5, 1Massachusetts General Hospital, Boston, MA, 2Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3Massachusetts General Hospital, Lexington, MA, 4Massachusetts General Hospital, Newton, MA, 5Massachusetts General Hospital , Harvard Medical School, Concord, MA

    Background/Purpose: Glucocorticoids (GC) are a backbone of treatment regimens for many rheumatic diseases despite their association with toxicities that contribute to excess morbidity and mortality.…
  • 1
  • 2
  • 3
  • …
  • 80
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology